Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tagarafdeg · CFT-1946

Small molecule (PROTAC degrader) · Degrader of BRAF V600E (BRAF)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Tagarafdeg?

Tagarafdeg is an orally bioavailable heterobifunctional protein degrader that binds the mutant BRAF V600E kinase and recruits the cereblon component of the CRL4-CRBN E3 ubiquitin ligase, leading to proteasomal degradation of BRAF V600E. It is being studied in solid tumors, melanoma, non-small cell lung cancer, colorectal cancer and anaplastic thyroid cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CFT-1946
Drug type
Small molecule (PROTAC degrader)
Targets
BRAF V600E (BRAF), cereblon (CRBN) (binding partner it blocks)
Mechanism
Degrader of BRAF V600E (BRAF)
Pathways
MAPK/ERK signaling, CRL4-CRBN E3 ubiquitin ligase-mediated proteasomal degradation
Therapy area
Oncology
In trials of
CCCC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
TT8PCR57MK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05668585 Phase 1 Solid Tumors Completed CCCC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ATCCRCMelanomaNSCLCSolid Tumors

Other drugs acting on BRAF

Flezurafenib Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.